Susquehanna International Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-250,700
Closed -$283K 14885
2022
Q2
$283K Buy
250,700
+234,713
+1,468% +$387K ﹤0.01% 9729
2022
Q1
$82K Sell
15,987
-12,120
-43% -$76.2K ﹤0.01% 12042
2021
Q4
$160K Sell
28,107
-11,840
-30% -$101K ﹤0.01% 11721
2021
Q3
$443K Sell
39,947
-7,806
-16% -$98.1K ﹤0.01% 9694
2021
Q2
$809K Buy
47,753
+10,273
+27% +$195K ﹤0.01% 8343
2021
Q1
$984K Sell
37,480
-707
-2% -$32.1K ﹤0.01% 7790
2020
Q4
$1.38M Buy
38,187
+14,814
+63% +$536K ﹤0.01% 5934
2020
Q3
$827K Buy
23,373
+12,406
+113% +$539K ﹤0.01% 6581
2020
Q2
$466K Buy
+10,967
New +$739K ﹤0.01% 7519

Other funds holding EVFM

Susquehanna International Group's EVFM Position: Q2 2022 in Review

Susquehanna International Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 45,113 shares — an estimated $74.4K sold.

Susquehanna International Group first reported a position in EVFM in Q3 2017 and held it in 10 quarters. The position peaked at $1.48M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Susquehanna International Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Susquehanna International Group sold 45,113 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $74.4K.
  • Susquehanna International Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2017 and held it in 10 quarters.
  • Susquehanna International Group's Evofem Biosciences, Inc. Common Stock position peaked at $1.48M in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.